Pfizer and BioNTech announced a three-shot course of Covid-19 vaccine was able to neutralise the new Omicron variant and can deliver an Omicron-based vaccine by March 2022. In an official statement on the efficacy of the dose, BioNTech and Pfizer said that two vaccine doses resulted in relatively low antibodies. Still, the third dose increased the neutralising antibodies by 25 per cent.

Many people are now fully vaccinated, and a booster is still the best approach to stop the spread of Covid-19,” Pfizer CEO Albert Bourla said in the statement. The findings are mainly of a study published by researchers at the Africa Health Research Institute in South Africa on Tuesday, saying that Omicron can somewhat bypass protection from two doses of the Pfizer/BioNTech vaccine, but also a third dose can help fend off the virus.